Alvotech takes AbbVie to court over alleged patent ‘minefield’ surrounding megablockbuster Humira

AbbVie has so far been successful in shooing away competition to its megablockbuster Humira, deploying a number of patents and settlements to keep biosimilars off the US market until 2023. But one Icelandic drugmaker doesn’t want to wait — and on Tuesday, it filed a lawsuit challenging what it called...

Click to view original post